Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Blood
Herman BurgerKees Nooter

Abstract

Imatinib mesylate (STI571), a potent tyrosine kinase inhibitor, is successfully used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. However, the intended chronic oral administration of imatinib may lead to development of cellular resistance and subsequent treatment failure. Indeed, several molecular mechanisms leading to imatinib resistance have already been reported, including overexpression of the MDR1/ABCB1 drug pump. We examined whether imatinib is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump that is frequently overexpressed in human tumors. Using a panel of well-defined BCRP-overexpressing cell lines, we provide the first evidence that imatinib is a substrate for BCRP, that it competes with mitoxantrone for drug export, and that BCRP-mediated efflux can be reversed by the fumitremorgin C analog Ko-143. Since BCRP is highly expressed in the gastrointestinal tract, BCRP might not only play a role in cellular resistance of tumor cells but also influence the gastrointestinal absorption of imatinib.

References

May 4, 1999·International Journal of Cancer. Journal International Du Cancer·H BurgerG Stoter
Aug 10, 2000·Biochemical Pharmacology·C H YangY C Chen
Aug 22, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·E Weisberg, J D Griffin
Sep 25, 2001·Blood·J M Goldman, B J Druker
Sep 29, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J VerweijA van Oosterom
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jul 9, 2002·British Journal of Haematology·Axel SauerbreyFelix Zintl
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Feb 8, 2003·The Lancet Oncology·Carlo B Gambacorti-PasseriniLeonardo Scapozza
Jun 11, 2003·European Journal of Clinical Investigation·M LindellM A Lang

❮ Previous
Next ❯

Citations

Sep 15, 2005·Die Naturwissenschaften·Toshihisa IshikawaHiroshi Nakagawa
Dec 25, 2010·Cancer Chemotherapy and Pharmacology·Wei-Lien WangJonathan C Trent
Feb 27, 2007·Cancer Metastasis Reviews·Robert W RobeySusan E Bates
Feb 27, 2007·Cancer Metastasis Reviews·Ying Huang
Jan 30, 2010·Cancer Metastasis Reviews·Georgios S Papaetis, Kostas N Syrigos
Feb 19, 2009·Journal of Mammary Gland Biology and Neoplasia·Michael Dean
Mar 24, 2007·Pharmaceutical Research·Sébastien BihorelJean-Michel Scherrmann
Jan 19, 2008·Pharmaceutical Research·Qingcheng Mao
Apr 29, 2010·Current Hematologic Malignancy Reports·Muriel MalaiseSelim Corbacioglu
Mar 21, 2012·European Journal of Drug Metabolism and Pharmacokinetics·Yun-Xia LiCheng Peng
Mar 1, 2013·European Journal of Drug Metabolism and Pharmacokinetics·C JoveletS Gil
May 7, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Eva KraljAlbin Kristl
Dec 15, 2011·Journal of Medicinal Chemistry·Glaucio ValdameriAttilio Di Pietro
Sep 17, 2010·Leukemia·D M RossJ V Melo
Feb 1, 2008·Nature Clinical Practice. Oncology·Stefan SleijferJaap Verweij
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Oct 6, 2005·Hematology·Mhairi CoplandTessa L Holyoake
Dec 3, 2011·Nucleosides, Nucleotides & Nucleic Acids·Akiyoshi NakayamaNariyoshi Shinomiya
Jan 22, 2008·Assay and Drug Development Technologies·Irena Ivnitski-SteeleBruce S Edwards
Nov 3, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J SeongY-R Yoon
Dec 7, 2006·Journal of the National Cancer Institute·George CusatisSharyn D Baker
Mar 8, 2006·Anti-cancer Drugs·Abdelhakim Ahmed-BelkacemAttilio Di Pietro
Dec 17, 2005·Current Opinion in Oncology·Federica Di Nicolantonio, Alberto Bardelli
Dec 6, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nagdeep GiriWilliam F Elmquist
Apr 29, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Marius DohseSusan E Bates
Sep 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shuiying HuSharyn D Baker
Dec 16, 2010·The Journal of Clinical Investigation·Amie S CorbinBrian J Druker
Dec 12, 2012·Genes & Cancer·Sourik S Ganguly, Rina Plattner
Jun 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine E Eyler, Jeremy N Rich
Sep 9, 2005·The AAPS Journal·Qingcheng Mao, Jashvant D Unadkat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.